Metraipolis › archive › dc_93ddac18212c

Clinical Applications of CDK4/6 Inhibitors in HR+/HER2, and Personalized Treatment Strategies: A Narrative Review — Europe PMC PMID:42220439

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42220439
DOI
10.32604/or.2026.076300
License (as archived)
solo-consultazione
Archived
2026-11-01T09:29:36.039Z
SHA-256 of the archived text
490e86572f5a3920f12f3a7ee611a922befc2f0480cf136eefd3a875c99d679f
Stable URL of this page
https://metraipolis.com/documento/dc_93ddac18212c

How to cite

Clinical Applications of CDK4/6 Inhibitors in HR+/HER2, and Personalized Treatment Strategies: A Narrative Review — Europe PMC PMID:42220439 — Europe PMC (en), https://europepmc.org/article/MED/42220439 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_93ddac18212c (Metraipolis archive dc_93ddac18212c, sha256 490e86572f5a3920f12f3a7ee611a922befc2f0480cf136eefd3a875c99d679f)
BibTeX
@misc{dc93ddac18212c,
  title = {Clinical Applications of CDK4/6 Inhibitors in HR+/HER2, and Personalized Treatment Strategies: A Narrative Review — Europe PMC PMID:42220439},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42220439},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_93ddac18212c; sha256 490e86572f5a3920f12f3a7ee611a922befc2f0480cf136eefd3a875c99d679f},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42220439. Agents can read the archived copy with the MCP tool read_document.